Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin-2) and Ipilimumab (Yervoy®) in Patients with Metastatic Melanoma
This research is being done to evaluate two drugs given in sequence (one after the other) including ipilimumab (also known as YervoyÂ®) and High Dose Interleukin-2 (abbreviated as HD IL-2 and known as ProleukinÂ®) in people with metastatic melanoma. Ipilimumab is approved by the FDA for the treatment ofmetastatic melanoma. HD IL-2 is also FDA-approved for the treatment of metastatic melanoma. Both drugs are approved for the same disease, although the two drugs have not been studied in sequence. The purpose of this research study is to evaluate the response of the disease to ipilimumab and HD IL-2when given in sequence (one after the other). The disease response to the series of drugs will be evaluated four (4) times during the study.
07/29/2014 04:02 AM